Pathology report with tumour subtype and molecular markers
tumour subtyping and assessment of molecular markers
tests per year, UK, once, at biopsy
“ensure they are adequate (without unacceptable risk to the person) to permit pathological diagnosis, including tumour subtyping and assessment of molecular markers.”
NICE NG122 Lung cancer, diagnosis and staging, 2026-11-06
- Kind of source
- Clinical guideline
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- Read from the guideline's own text.
Used in
Kept as evidence; no figure on the platform is computed from it yet.